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Abstract 
Association between histones and DNA is crucial for many cellular functions such as gene 
transcription and epigenetic silencing. Changes to chromatin structure influence gene expression 
via histone modifications. Chromatin immunoprecipitation (ChIP) is an experimental technique 
used to investigate the interactions between histones and DNA. ChIP determines the specific 
location in the genome that histone modifications are associated with, indicating the target of the 
histone modifiers. Despite the appeal of ChIP as an in vitro technique, there are limitations to its 
use. There is variability from one preparation to the next, given the many steps and reagents used 
throughout the technique. No one has been able to demonstrate consistent results in a clinical 
population using white blood cells. It was established, for the first time, the normal variability of 
ChIP results in THP-1 cells, Jurkat cells, TF-1a, and human male circulating leukocytes over 
time for histone modifications H3k4me3 and H3k9Ac. 
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Chapter 1: Introduction and Background 
Introduction 
The term epigenesis first appears in 1651, used by English physician William Harvey 
(1578–1657) in his Exercitationes, and again 1653, in the English Anatomical Exercitations. He 
defined epigenesis to mean the “additament of parts budding out of another” in his argument that 
all living beings gradually developed from eggs into complex beings based on Aristotle’s theory 
of embryonic development (Zumbo, 2013). From this, C.H. Waddington coined the term 
epigenetics in 1942, as pertaining to the differentiation of cells from their pluripotent state during 
embryonic development (Waddington, 1942). Waddington coined this term before the discovery 
of the physical nature of genes and their role in heredity. Instead, he was theorizing on how 
genes and their environment interact to produce a phenotype. The word “epigenetics” has been 
defined and redefined based on the knowledge of biology and genetics at the time. The term has 
further evolved as contemporary biologists refer to epigenetics simply as how genetic material 
can be activated or deactivated based on their environment. However, this definition doesn’t 
include processes that may be transient and not heritable. In 2008, a consensus definition was 
created to define the epigenetic trait as “stably heritable phenotype resulting from changes in a 
chromosome without alterations in the DNA sequence” (Berger et al., 2009). Currently, the 
National Institutes of Health (NIH) Roadmap Epigenomics Project maintains “…epigenetics 
refers to both heritable changes in gene activity and expression and also stable, long-term 
alterations in the transcriptional potential of a cell that are not necessarily heritable” (NIH, 2010).  
The NIH definition will be used for the purposes of this study.   
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Epigenetic Processes 
Epigenetics is a method of genetic control by means other than an individual’s DNA 
sequence. Epigenetic changes alter gene expression and determine which genes are transcribed 
for protein translation. Control of gene expression is important when considering that all of an 
organism’s cells have the same DNA, but cells differentiate into numerous cell types each with 
unique characteristics and functions based on the patterns of gene expression. Both properties of 
the DNA and components of the cell’s environment influence these expression patterns as is 
readily apparent in embryonic development. Cells in an embryo have the option to differentiate 
based on their genetics, but the influences from their environment play an important role in 
determining their development. Multiple layers of epigenetic influence are required to ensure 
proper development in the embryo. Epigenetic states have to be first established and then 
maintained throughout development to ensure maintenance and carry-over of the developmental 
identity of each cell as the embryo develops (Das, 2016). Cells, tissues, and organs differ 
because epigenetic control determines which genes are turned off, or repressed, and which genes 
are turned on, or expressed (Simmons, 2008). Specifically, epigenetic regulation is important for 
X-chromosome inactivation in female mammals ensuring females do not have twice the number 
of X-chromosome gene products as males (Egger et al., 2004).  
Epigenetic processes are natural and essential in regulating many cellular functions and 
therefore can contribute to pathology if disrupted, leading to major adverse health and behavioral 
effects. A growing body of evidence shows that inappropriate epigenetic processes are key 
contributors to autoimmune diseases and cancer (Wen et al., 2008). Epigenetic mechanisms help 
establish cellular identities, and failure of the proper preservation of epigenetic marks results in 
inappropriate activation or inhibition of various cellular signaling pathways leading to pathology 
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of cancer and other disorders (You & Jones, 2012). Epigenetic processes can be divided into 
three systems that interact with each other to regulate gene expression patterns related to healthy 
and diseased states: 1) DNA methylation, 2) RNA-associated silencing, and 3) 
histone modifications (Egger et al., 2004). This study focused on the epigenetic histone 
modifications. 
 
Histone Modification 
 Chromatin is the state in which DNA is packaged within the cell. The nucleosome is the 
foundational unit of chromatin and is composed of an octamer of four core histones—H3, H4, 
H2A, H2B—that act as a spool for DNA to wrap around (Simmons, 2008). The core histones are 
globular except for their N-terminal tails, which are unstructured and can be modified. When 
histones are modified, they influence how chromatin is arranged in three-dimensional space. This 
arrangement determines whether the promoter region of a gene that is associated with the DNA 
will be transcribed, i.e., whether the gene is turned on. When chromatin is condensed, creating 
the complex called heterochromatin, the promoter region of the DNA is not available for 
transcription, and the gene is repressed, or turned off. When chromatin is not condensed and the 
DNA is loosely spooled around the histones exposing promoter regions of genes, DNA 
transcription can occur, allowing for gene expression (Simmons, 2008).   
Several post-translational covalent modifications of the N-terminal tails of each histone 
have been identified and include acetylation, methylation, ubiquination, sumoylation, and 
phosphorylation. The two main histone modifications are acetylation and methylation, resulting 
in adding either an acetyl or methyl group, respectively, to the amino acid lysine within the 
histone tail.  Lysine acetylation is usually associated with active chromatin, while deacetylation 
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is generally associated with condensed chromatin. On the other hand, histone methylation can be 
a marker for both active and inactive regions of chromatin (Simmons, 2008). For example, 
methylation of a particular lysine (K9) on a specific histone (H3) that marks silent DNA is 
widely distributed throughout heterochromatin. This type of epigenetic change is responsible for 
the inactivated X chromosome of females. In contrast, methylation of a different lysine (K4) on 
the same histone (H3) is a marker for active genes (Egger et al., 2004). There are over 60 
different residues on histones where modifications have been detected (Kouzarides, 2007). This 
number is misleading, however, because multiple modifications can take place on a single 
histone, influencing the 3-D structure of the histone. In addition to multiple modifications, 
methylation at lysines within the histones may take one of three forms: mono-, di-, or 
trimethylation (Kouzarides, 2007). The timing of modifications will depend on signaling 
conditions in the cell based on factors such as an organism’s age, diet, and exposure to 
chemicals.  
Histone modifications have been linked to a number of chromatin-dependent processes, 
including replication, DNA repair, and gene transcription (Karlic et al., 2010).  These 
modifications may be dynamic as the transcriptional state of a gene changes, particularly during 
cell differentiation. However, the ability of these chromatin modifications to persist through cell 
division and thus allow a cell to “remember” its transcriptional profile and, by extension, its 
cellular identity, defines epigenetic regulation (Zediak et al., 2011). 
 The concept that a gene phenotype can be maintained over a long period of time and is 
heritable through histone modification is thought to be due to the fact that the DNA is not 
completely stripped of its nucleosome after replication. This means the remaining modified 
histones can act as templates to initiate the same modification of new histones during replication 
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(Turner, 2002).  Thus, any modification to the histones can be transferred to daughter cells 
during replication allowing for the transfer of the “histone code.”  
Figure 1 demonstrates how DNA is packaged into nucleosomes and how modifications to 
the histone tail dictate gene activity. Chromatin structure is dynamic in that it constantly changes 
in response to external stimuli. Substantial evidence has been accumulated to suggest that the 
cellular state is closely related to the chromatin state, particularly modifications of histones. In 
addition to defining and controlling gene expression patterns, chromatin modifications also 
determine a cells’ response to environmental or developmental cues regarding its transcriptional 
output (Jayani et al., 2010). 
 
Figure 1.  Histone modification occurs when the binding of epigenetic factors to histone "tails" 
alters the extent to which DNA is wrapped around histones and the availability of genes in the 
DNA to be activated (NIH, 2013). 
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Histones 
 This study focused on two specific histone modifications: methylation of lysine 4 on 
histone 3 (H3k4me3) and acetylation of lysine 9 on histone 3 (H3k9Ac). H3k4 was first 
discovered in trout testes in 1975, ten years after lysine methylation of histones was first 
described (Honda et al., 1975; Murray, 1964). Subsequent studies linked H3k4 to transcriptional 
activation in a variety of eukaryotic species (Ruthenburg, 2006). It is thought that high levels of 
H3k4me3 are associated with the promoter regions of most active genes and that there is a strong 
positive relationship between this modification, transcription rates, and histone acetylation 
(Eissenberg & Shilatifard, 2009). Methylation may affect DNA accessibility in two ways: by 
affecting a conformation change of the histone directly or by creating a binding site for proteins 
that will then alter the properties of the chromatin for transcription (Eissenberg & Shilatifard, 
2009).   
One of the most studied modifications of histones is acetylation of specific lysine (K) 
residues, which generally correlates with gene activation. The level of histone acetylation is 
regulated by the activity of both histone acetyl transferases (HATs) and histone deacetylases 
(HDACs), which acetylate and deacetylate lysine residues of the N-terminal histone tails, 
respectively (Karmodiya, 2012). Histone acetylation plays essential roles in transcriptional 
initiation and elongation and is known to open the chromatin structure at the respective promoter 
sites to activate transcription (Hansen, 2006). H3K9Ac, which is a histone modification 
associated with open chromatin, is enriched at gene promoters with various genomic features and 
highly correlates with gene expression (Qiao, 2014). H3K9Ac is present at different sets of gene 
promoters associated with cell identities and enables active transcription with cell type-specific 
patterns (2014).  
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Several methods have been developed to address questions concerning the interactions 
involved in chromosome structure and nuclear organization. Histones are part of maintaining the 
genomic landscape within the cell (Jayani et al., 2010). The spatial and temporal changes 
involved in histone modifications dictate the active, inactive, or poised status of a particular 
gene. Earlier methods developed to study the DNA-protein interactions involve in vitro methods; 
however, these have limited use because they do not operate within the context of the cell (Das et 
al., 2004).  Chromatin immunoprecipitation (ChIP) has become a widely used technique in 
determining the location of various transcription factors, histones, and other proteins.  
 
Chromatin Immunoprecipitation 
A key determinant in deciding the merit of a technique used to study histone 
modifications and gene activity is the ability to provide direct evidence that proteins are 
associated in time and space with specific genome regions (Orlando, 2000). Chromatin 
immunoprecipitation (ChIP) has become the technique of choice to investigate protein-DNA 
interactions inside the cell (Collas, 2010). The principle of the ChIP assay is demonstrated in 
Figure 2. DNA and proteins are cross-linked with formaldehyde to covalently attach proteins to 
DNA sequences. The formaldehyde cross-links the proteins and DNA very closely to each other, 
thus making the assay suitable for looking at proteins, such as histones, that bind directly to 
DNA. Because the proteins are captured at the sites of their binding with the DNA, ChIP helps to 
detect DNA-protein interactions within living cells. The chromatin is then fragmented using 
sonication, into segments of 200–1000 base pair (bp). Antibodies specific to the protein of 
interest are used to precipitate protein-DNA complexes. The cross-link is reversed, the protein is 
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digested, and the DNA is released from the complex, purified, and analyzed using various 
follow-up techniques (Collas, 2010).  
 
Figure 2. Chromatin Immunoprecipitation (ChIP) assay and analysis techniques (Collas, 2010). 
Copyright by Humana Press. Reprinted with Permission. 
 
For a long time, a major disadvantage of ChIP has been the requirement for large cell 
numbers, typically 20 to 30 million cells. This large cell number is necessary to compensate for 
the loss of cells after cross-linking, as well as the overall inefficiency of ChIP. The need for large 
cell numbers has limited the application of ChIP in sample from humans, potentially preventing 
its use in non-tissue clinical samples. Alterations to conventional ChIP protocols are aimed at 
making the technique applicable to smaller cell numbers (Collas, 2010). 
 
Purpose of the Study 
While ChIP is a versatile technique, it requires the optimization of several processing 
conditions for successful DNA isolation (Das, 2004) and subsequent accurate results. For almost 
two decades, ChIP remained a cumbersome protocol, requiring several days and large numbers 
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of cells—multimillion cells per immunoprecipitation. ChIP assays typically involve extensive 
sample handling leading to a loss of DNA and allowing for technical errors and decreased 
consistency between replicates (Collas, 2010). This limits our understanding of ChIP results 
reported in scientific literature, typically reported as fold changes or a percentage of DNA input. 
It is important to determine if the results of ChIP assays are biological or technical in nature. The 
vast majority of studies done using ChIP in the clinical setting involve tissue biopsies, with ideal 
yields of 10 million cells (O’Neill, 2006). This may mask any technical issues and 
inconsistencies between samples. With the development of less invasive biopsy techniques and 
clinical diagnostics requiring less biological material, it becomes imperative that ChIP assays 
adapt to fewer cells. One aim of this study was to demonstrate the biological and technical 
variability present when using a small cell number in ChIP assays.    
Because epigenetics has become an expanding field of study in immunology, studies 
indicate that epigenetic mechanisms can govern immune responses, productive and deleterious. 
In particular, histone methylation has been implicated in the development of acquired immune 
responses, such as the long-term suppression of the host’s immune system after severe sepsis 
(Wen, 2008). However, most of this evidence has been acquired using in vitro studies associated 
with T cell activity. Recent studies conducted on white blood cell (WBC) populations, 
particularly peripheral blood mononuclear cells (PBMCs) from human subjects still use large cell 
numbers (>10 million), requiring 10 milliliters of blood (Zhang, 2009; Wen 2008). In a healthy 
adult, there is a range 0.84–2.64 x 106 PBMCs per mL of whole blood (Mayo Clinic, 2016). That 
value increases in the pediatric population, from 1.5 x 106 to as many as 1.1 x 107 cells/mL 
(Mayo Clinic, 2016). That number drops precipitously with an acute immune response as the 
cells leave the peripheral blood to respond to the source of inflammation. Based on extensive 
CHROMATIN IMMUNOPRECIPITATON 
 10 
literature searches using PubMed and sources cited within scientific papers, there are no studies 
demonstrating consistent ChIP results in a clinical population using WBCs in small numbers. 
Those few studies done on WBCs give no indication of what researchers can expect for a control 
or “normal” individual. The second aim of this study was to demonstrate that variability in small 
cell number ChIP assays on WBCs is due to individual changes over time while defining normal 
ranges for subjects serving as controls. 
 
Significance of the Study 
 Establishing a normal range from ChIP assays performed on control organisms becomes 
important when considering the fact that many therapeutics, particularly in cancer, involve 
disrupting histone modifications. Histone deacetylase inhibitors (HDACi), in particular, have 
been intensely scrutinized for the past decade. As previously described, acetylation has been 
linked to a chromatin state that is poised for transcription or that corresponds to actively 
transcribed genomic regions (Minucci & Pelicci, 2004). The HDACi are a small group of 
molecules that target histone deacetylases (HDACs), preventing those genomic regions 
associated with acetylated histones from being repressed. Many HDACi have entered Phase I 
through III clinical trials and two, vorinostat and romidepsin, have the approval of the Food and 
Drug Administration (FDA) in the treatment of lymphomas (Slingerland, 2014). Epidrugs are 
drugs that inhibit or activate disease-associated epigenetic proteins for ameliorating, curing, or 
preventing the disease (Ivanov et al., 2014). Table 1 shows HDACi epidrugs currently in clinical 
use and under investigation. HDACi are also currently under investigation for the treatment of 
schizophrenia (Hasan et al., 2013). In the field of immunology, HDACi are under investigation 
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for the treatment of rheumatoid arthritis, systemic mastocytosis, acute myeloid leukemia, and 
lupus (Grabiec et al., 2012; Abdulkadir et al., 2015; Lubbert, 2015; Guo et al., 2014).  
Table 1. Epidrugs Currently Approved or in Clinical Trials (Ivanov et al, 2014). 
HDAC Inhibitors Clinical Application 
Valproic Acid Promising nontoxic and effective therapy for MDS in combination 
with hydralazine (Phase II trial) 
Under evaluation in metastatic cervical cancer in combination with 
hydralazine (Phase III trial) 
Combined with ada-dC for non-small-cell lung cancer (Phase I 
trial) 
Suberoylanilide hydroxamic 
acid (vorinostat, Zolinza) 
Approved by the FDA in 2006 for treatment of advanced cutaneous 
T-cell lymphoma 
Reversed hormone resistance in patients with ER metastatic breast 
cancer, when co-administered with tamoxifen (Phase II trial) 
Romidepsin        
(depsipeptide Istodax) 
Approved by the FDA in 2009 for treatment of advanced cutaneous 
T-cell lymphoma 
Sodium butyrate Induces antimicrobial peptide LL-37 in the rectum of shigellosis 
patients (Phase II trial) 
Panobinostat Promising results in monotherapy of heavily pretreated Hodgkin's 
lymphoma patients (Phase II trial) 
Recaptures responses in bortezomib-resistant multiple myeloma 
patients (Phase II trial) 
Entinostat Improved survival in women with ER advanced breast cancer when 
added to exemestane (Phase II trial) 
Mocetinostat 
Promising effect in monotherapy of relapsed Hodgkin's lymphoma 
(Phase II trial) 
Selisistat Under evaluation for treatment of Huntington's disease (Phase II 
trial) 
 
Histone methyltransferases are being investigated in relation to gliomas, autoimmune 
disorders, breast cancer, and pulmonary viral infections (Erfani et al., 2015; Xia et al., 2013; Salz 
et al., 2015; de Almeida Nagata et al., 2015). The primary method in determining the activity of 
these histone modifiers is ChIP. Understanding the impact any of these molecules may have on 
epigenetic processes may be crucial. For example, HDACi are not without risks; HDACs are an 
integral part in transcriptional silencing of HIV and inhibiting them results in a disruption of HIV 
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latency (Shirakawa, 2013). Understanding the potential risks, as well as the benefits, is essential 
to the success of any of these molecules as clinical treatments.  
Blood volume was another area of potential significance for this study. In previous 
studies, 10 mL of blood was taken from individuals in order to get enough cells to satisfy the 
demands of the ChIP assay. However, if an investigator wanted to use the ChIP assay to look at 
histone modifications in the presence or absence of a drug or other physiological stimuli in the 
pediatric population, that would pose a significant problem. Most, if not all institutional review 
boards (IRB) impose limits on how much blood may be removed from an individual over a 
three-month period based on body weight. If blood is needed for multiple diagnostics, it becomes 
essential that ChIP assays can be done in smaller cell numbers. 
 
Limitations of the Study 
The ChIP assay is useful for studying DNA-protein interaction, but it is more of a 
qualitative study than a quantitative approach. It is possible to determine if a specific DNA 
sequence is associated with a specific protein, but it’s difficult to establish that the association is 
true for every cell in the cell lysate. The quantification of DNA may be misleading because the 
crosslinking with formaldehyde is never complete. If that were the case, it would be impossible 
to isolate and purify DNA fragments from the cross-linked nuclear DNA. This means that there 
will be variability in the crosslinking from one sample preparation to the next. Another factor is 
the immunoprecipitation step. From one experiment to the next, the antibody may not bind 
efficiently to the entire antigen in the sample. Finally, there may be variability in the washing 
step.  Washing the beads can result in the removal of the antibody or the antigen from the beads 
(Das et al., 2004). 
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In addition to limitations in the ChIP assay, there are limitations to this study. The use of 
cells in culture may provide a different picture than that of primary cells isolated from an 
organism. Cell lines commercially available for culturing are immortalized or transformed due to 
a genetic alteration that allows them to divide indefinitely. The sources of these cell lines are 
often cancers and after a period of growth in culture, cell characteristics can change. This can 
result in inconsistent ChIP data, as there is already a shift in the genetic and epigenetic 
machinery in these cell lines. Using primary cells from human subjects presents its own 
challenges. A study to determine the normal ranges of histone modifications in healthy subjects 
may require a number larger than used in this investigation. 
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Chapter 2: Review of Related Literature 
 Chromatin immunoprecipitation (ChIP) is a powerful tool in the application of antibody 
techniques to epigenetic research providing researchers a detailed analysis of histone 
modifications. However, conventional ChIP requires large numbers of cells, limiting its 
application to cell culture models that provide large numbers of homogenous cells (O’Neill et al., 
2005). This study focused on primary cells isolated from whole blood, specifically peripheral 
blood mononuclear cells (PBMCs).  
 A small number of studies conducted in the last ten years used PBMCs in their 
investigations into epigenetic modifications using ChIP-qPCR. Bosch and her associates (2002) 
conducted one of the earliest studies in PBMCs by collected 120 mL of blood from healthy 
human volunteers to study interleukin-8 (IL-8) transcription regulation in response to in vitro 
stimulation to dengue fever. They showed increased IL-8 transcription and production using 
western blot to demonstrate an increase in histone acetylation. In 2007, Miao and associates 
isolated 50 mL of blood from adults characterized as healthy, with type I diabetes, or type II 
diabetes. They reported their ChIP data in arbitrary units, comparing healthy adults to those with 
either form of diabetes, demonstrating that H3k4me2 distribution patterns are comparable among 
individuals (Miao, 2007). Sullivan (2007) used monocytes isolated from an undisclosed volume 
of blood drawn from adult patients diagnosed with lupus and healthy volunteers. She expressed 
her data as normalized units, doing a side-by-side comparison of patient versus control in their 
expression of tumor necrosis factor alpha (TNF) to show that H4 acetylation and H3k4me3 
increased early in transcription. In 2008, Miao again used 50 mL of blood from healthy 
volunteers to study histone modification at core genes, using ratios to analyze ChIP data. Zhang 
(2009) collected 10 mL of blood from 15 adults suffering from minimal change nephrotic 
CHROMATIN IMMUNOPRECIPITATON 
 15 
syndrome, an immunologically mediated disease. This trend of using large volumes of blood 
continues presently. 
 Only two studies have used smaller volumes of blood. The first was in 2008 by Wen, 
who isolated T cells from mouse spleen to investigate the relationship between histone 
modifications and interleukin-12 expression. Wen and his colleagues cross-linked 1 million cells 
for their ChIP assays, similar to the aims of this study. They also expressed their results as a 
percent of total DNA. However, their numbers raise questions. In many of their assays, the 
percentages calculated range from 0.1 to 0.8% to show histone status at the promoter regions of 
their genes of interest. In the process of doing a literature search, it was clear that most reports of 
percent input in ChIP assays range from 10% to 80%, as in Gurvich’s study from 2004 and in 
Gemelli’s study in 2014. This raises questions on just how Wen chose to calculate his data. Also, 
Wen used a 2% input DNA isolation for use in their qPCR rather than the standard 1%. Using 
more input DNA drives the percent input value down. 
 In the second study, Cornell et al. (2012) isolated PBMCs from whole blood using a 
protocol similar to the one used in this study. They collected 4 mL of blood from pediatric 
patients undergoing cardiopulmonary bypass (CPB) into cell preparation tubes to separate 
PBMCs from red blood cells. However, in analyzing the ChIP data, fold changed, rather than 
percent input, was used to compare post-CPB to pre-CPB. This method of analysis was 
appropriate for the purposes of that study. However, it presents no insight as to what “normal” 
values look like in healthy individuals. Nor does it, or any study, show a temporal profile for 
histone modification changes over time in healthy individuals.  
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Chapter 3: Research Design and Methodology 
Reproducibility 
 
Due to the inherent variability involved in any in vivo study, it is important to 
demonstrate the reproducibility of chromatin immunoprecipitation (ChIP) using a cell culture 
model. This provides investigators with a baseline for determining if variability seen in human 
participant samples is due to technique or biological variability. Using a ChIP assay suitable for 
low cell numbers from Dahl and Collas (2007) as shown in Figure 3, changes in two histone 
modifications on the promoters of three genes regulated by the immune environment were 
monitored. ChIP was used on three cell culture lines, Jurkat (Clone E6-1), THP-1, and TF-1a 
cells (American Type Culture Collection, Manassas, VA, www.atcc.org), to demonstrate the 
reproducible nature of the technique in controlled cell populations.  
 
Figure 3. Summary of the ChIP procedure (Dahl and Collas, 2007). Copyright 2007 by John 
Wiley and Sons. Reprinted with permission. 
 
Jurkat cells, T cells established from acute T cell leukemia, were cultured in RPMI-1640 
supplemented with 10% fetal calf serum. Cells were passaged every 3 days such that cell density 
did not exceed 3 x 106 cells/ml. THP-1 cells, monocytes derived from acute monocytic leukemia, 
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were cultured in RPMI-1640 supplemented with 10% fetal calf serum and 2-mercaptoethanol to 
a final concentration of 0.05 mM. Cells were passaged every 3 days so as to maintain a cell 
density between 4 x 105 and 8 x 105 cells/mL. TF-1a cells, lymphoblasts established from 
erythroleukemia, were cultured in RPMI-1640 supplemented with 10% fetal calf serum. Cells 
were passaged every 3 days to maintain a cell density between 3 x 105 and 3 x 106 cells/mL. 
These cell lines were chosen to mimic the cell types found when isolating peripheral blood 
mononuclear cells (PBMCs) from human participants.   
DNA-Protein Crosslinking. Cells were harvested and processed as follows. Each of the 
cell lines was cultured in 150 cm3 tissue culture flasks, in a total volume of 75 mL of media. 
Within 12 hours of passage, two aliquots of 1-2 x 106 cells were isolated from the flasks and the 
volume of cells removed was replaced with fresh media. Subsequent aliquots were removed from 
the flasks the following two days, for a total of 6 aliquots from 3 consecutive days from the same 
passage. Cells were centrifuged and washed with phosphate-buffered saline (PBS), then 
resuspended to 1-2 x 106 cells per 500 microliters of PBS. Formaldehyde was added to 1% 
(vol/vol) and allowed to fix the cells for 10 minutes at room temperature. The reaction was 
stopped with 125 mM glycine for 5 minutes at room temperature. Cells were placed on ice or at 
4°C and processed as follows.  Cells were washed by centrifugation and suspension in PBS. 
Cells were lysed for 5 minutes in 150 uL of lysis buffer (50 mM Tris-HCL, pH 8.0, 10 mM 
EDTA, 1% SDS, protease inhibitor cocktail, 1 mM PMSF) containing 20 mM sodium butyrate. 
The cells were then flash frozen in liquid nitrogen and stored at -80°C.   
Antibody-Bead Complexes. Antibodies against H3k9Ac (catalog number C15410004) 
and H3k4me3 (catalog number C15410003-50) were acquired from Diagenode (Denville, NJ, 
www.diagenode.com). Paramagnetic beads (Dynabeads Protein A; ThermoFisher Scientific, 
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Waltham, MA, www.thermofisher.com) were washed twice in Pierce RIPA buffer 
(ThermoFisher Scientific) and resuspended in 1 volume of RIPA buffer. Beads (10 μL) were 
added to 90 μL of RIPA buffer and 2 μg of primary antibody in a 0.2 mL tube and incubated on a 
rotator (HulaMixer; ThermoFisher Scientific) for 2 hours at 4°C. The tubes were in 8-tube strips 
and handled in parallel in an aluminum magnetic rack (DiaMag 0.2 mL, Diagenode) and chilled 
on ice. 
Sonication. One aliquot from each day of cell isolation was sonicated for 15 x 30 seconds 
in ice-cold water (Bioruptor; Diagenode) with 30 second pauses to produce chromatin fragments 
of ~200 base pairs. The lysate was centrifuged at 10,000 x g for 10 minutes, and the supernatant 
was collected into fresh tubes. Chromatin was diluted to a concentration of 1-2x106 cells/mL. 
Immunoprecipitation. The tubes containing the antibody-bead complexes were placed in 
magnets to hold the complexes to the tube wall. The supernatant was removed and replaced with 
100 μL of sheared chromatin containing material from 105 cell equivalents. The beads were 
released into the chromatin suspension and rotated at 40 rpm overnight at 4°C.   
Washes. Immune complexes were washed three times by capturing the beads with the 
magnet and releasing them in fresh 100 μL of RIPA buffer and once in TE buffer (10 mM Tris-
HCl, pH 8.0, 10 mM EDTA).  Each wash lasted 4 minutes at 4°C. 
DNA Elution, Crosslink Reversal, Proteinase K Digestion. Chromatin suspended in TE 
was transferred to a new 1.5 mL tube to reduce background in the end product.  The beads were 
captured by magnet (DiaMag 1.5 mL, Diagenode), the TE was removed, and 100 μL of elution 
buffer (20 mM Tris-HCl, pH 7.5, 5 mM EDTA, 20 mM sodium butyrate, 50mM NaCl) 
containing 1% SDS and 50 μg/mL proteinase K (Sigma-Aldrich, St. Louis, MO, 
www.sigmaaldrich.com) were added. Samples were incubated for 2 hours at 68°C on a 
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Thermomixer (Eppendorf North America, Hauppauge, NY, www.eppendorf.com) at 1300 rpm. 
After capturing the beads, the supernatant was recovered for DNA isolation. ChIP is assumed to 
precipitate less than 1% of nucleosomes, so a 1/100 dilution of the diluted sheared chromatin was 
treated to DNA elution, crosslink reversal, and proteinase K digestion in parallel with the 
immunoprecipitated samples. 
DNA Isolation. The DNA was extracted by adding 180 μL Agencourt AMPure XP beads 
(Beckman Coulter, Indianapolis, IN, www.beckmancoulter.com) to the chromatin to incubate for 
2 minutes. The beads were washed twice by capture and release into 70% ethanol. After the last 
wash, the beads were allowed to dry to ensure the removal of the ethanol. The beads were then 
resuspended in UltraPure water (ThermoFisher Scientific). The beads were captured again and 
the supernatant, containing DNA, was recovered. 
Polymerase Chain Reaction. Input DNA and immunoprecipitated DNA were analyzed in 
triplicate by real-time PCR on a StepOnePlus Real-Time PCR System (ThermoFisher Scientific) 
using Power SYBR Green PCR Master Mix (ThermoFisher Scientific). PCR Conditions were 
95°C for 3 minutes and 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 
seconds. The ChIP assay was repeated 24 hours later on the second aliquot from each day of cell 
isolation as a means of examining technical reproducibility.  
 The DNA primers chosen for real-time PCR, shown in Table 2, are the promoter regions 
for cytokines that regulate inflammation. Tumor necrosis factor alpha (TNF) has a major role in 
early inflammatory responses as a pro-inflammatory cytokine (Sullivan, 2007). Interleukin-10 
(IL10) is also an important cytokine in the regulation of immune responses. It serves mainly as 
an anti-inflammatory cytokine, functioning to inhibit the production of pro-inflammatory 
cytokines. IL10 is also noted to have pro-inflammatory capabilities, promoting B cell 
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proliferation and antibody production (Larsson et al., 2012). Interleukin-12 (IL12) is another 
important cytokine that is important in the pro-inflammatory immune process. It is composed of 
two subunits, p35 and p40, and its protein is functional as a heterodimer of p35 and p40 as well 
as a homodimer of p40 (Kalinski et al., 1997). Primer pairs were used to amplify the promoters 
of TNF, IL12 p35, and IL12 p40; two primer pairs were used to amplify the promoter of IL10, 
IL10-233, and IL10-531. 
Table 2. Real-time ChIP Primers Used in This Study. 
 
 
Gene 
Forward primer 5’ – 3’ 
Reverse primer 5’ – 3’ 
TNF kB3 TACCGCTTCCTCCAGATGAG 
TGCTGGCTGGGTGTGCCAA 
IL-10 233 GCTGTAATGCAGAAGTTCATGTTC 
AGGGAGGCCTCTTCATTCA 
IL-10 531 GGGACAGCTGAAGAGGTGGA 
CCTCAAAGTTCCCAAGCAGC 
IL-12 p35 CCTGGCATCTAGTGAGCCAT 
GTGTCTAAGCTACCCCGCC 
IL-12 p40 TATTCCCCACCCAAAAGTCA 
CTGCTGTTGCTGGTACTGGA 
 
 
Reliability 
Once reproducibility was demonstrated in cell culture, investigation continued in a group 
of five healthy participants, all Caucasian males aged 25–50. Stored samples were obtained from 
a study, HUM00074806, approved by the IRB at the University of Michigan (Appendix A). 
Eastern Michigan University IRB determined that this study did not require review because 
samples were previously obtained (Appendix B). Blood was drawn from participants on three 
consecutive days and then once a week for three weeks. Four milliliters was drawn via 
venipuncture in a laboratory setting on each day and placed into cell preparation tubes (CPT; 
Becton Dickinson, Franklin Lakes, NJ, www.bd.com) with sodium citrate. Peripheral blood 
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mononuclear cells (PBMCs) were isolated from these blood samples for use in ChIP by 
centrifuging tubes at 3000 rpm for 30 minutes. The plasma layer was discarded and cells in the 
remaining buffy coat were removed to 1.5 mL tubes. The cells were counted and divided into 
aliquots of 2 x 106 cells per milliliter. The samples were then immunoprecipitated using the ChIP 
assay detailed above. One aliquot from each individual’s six time points were 
immunoprecipitated in parallel to minimize any technical variability.   
 
Statistical Analysis 
% of Input. Once the ChIP assay was complete, real-time PCR (qPCR) was performed on 
each of the cell lines using all the above DNA primers. The qPCR technique did not quantify the 
amount of PCR product at the end of the PCR reaction. Rather, the initial amount of template 
DNA was calculated from the kinetics of the PCR reaction. The accumulation of PCR product 
was measured every cycle using DNA-dye based detection chemistry (Haring et al., 2007). In 
this study, Power SYBR green was used as it fluoresces when bound to double-stranded DNA 
and the amount of fluorescence was proportional to the amount of double-stranded DNA. The 
number of cycles needed to reach a certain amount of PCR product, the cycle threshold or CT 
value, was used in calculations. The efficacy of chromatin immunoprecipitation of a particular 
genomic locus was calculated as a percentage of starting material: 
% (ChIP/ Total input) = 2^[(Ct(x%input) – log(x%)/log2) – Ct(ChIP)] x 100% 
Ct(ChIP) and Ct(x%input) were CT values obtained from qPCR for the immunoprecipitated 
sample and input sample. Log(x%)/log2 accounts for the dilution of the input, in this study the 
dilution is 1:100, so the value was 6.6. The study used percent input for all of the statistical 
analysis. 
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 In understanding the qPCR data from the cell culture portion of the study, two means of 
analysis were performed. First, all percent input values were aggregated to study how genes 
behaved at either histone modification site. The mean, standard deviation, and coefficient of 
variation were calculated. Second, a paired t test were applied to the two replicates from each 
day of cell isolation to determine whether the mean of the differences between the two match 
samples varies significantly. 
 In analyzing the qPCR data from the human samples, the data points for each individual 
were paired, in that several observations were linked to a specific individual. This was directly 
related to the fact that there was a genetic component to the response. This automatically 
eliminated any independent sample tests. There were more than two observations linked to an 
individual, which ruled out two sample testing. Because it was assumed that data meet 
assumptions of normality and homoscedasticity, two-way ANOVA was the preferred method of 
statistical analysis for understanding the influence of individual epigenomics and time on histone 
modification at each gene promoter location. In addition, the mean, standard deviation, and 
coefficient of variation were calculated for each participant in order to understand the reliability 
of the ChIP assay in normal human participants. 
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Chapter 4: Presentation and Analysis of Data 
 The first step in analyzing the chromatin immunoprecipitation (ChIP) assay is to 
determine the efficacy of the cell shearing. After the shearing step, a 10 l aliquot of chromatin 
was removed from each tube and digested with proteinase K at 55C for an hour. The chromatin 
was then loaded on a 2% agarose gel, along with a 100 bp ladder.  Using electrophoresis, 
fragments of DNA were separated by size. As shown in Figure 4, the bands across cell types 
were consistently under 500 bp in length, indicating successful chromatin shearing.    
 
 
 
           Jurkat                            TF-1a                              THP-1 
 
Figure 4. Image of sheared DNA from the three cell lines. 
 The percent input values for all three cell isolations and their two aliquots were combined 
to calculate the overall mean for each cell line, at each gene’s promoter region(s) at each histone 
modification site. Figure 5 illustrates the mean and standard deviation for each target of interest 
in THP-1 cells. One pattern that presents itself is the higher percentage of input at each promoter 
for H3k4me3 compared to that of H3k9Ac. This may be due the fact that histone acetylation is 
thought to strongly correlate with gene activation while histone methylation is associated with 
both gene activation and repression. Because the cells are believed to be in a homeostatic 
environment with no immune system signals in which to respond, gene activity is minimal. 
 
500 bp  
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Figure 5. Mean with standard deviation of all ChIP assays on THP-1 cells. 
 Looking at the numerical analysis in Table 3, the standard deviation ranges from 1.3 to 
6.2% for H3k4me3 and 1.1 to 5.3% for H3k9Ac. The coefficient of variation has a relatively 
wide range at H3k4me3, 9.4 to 23.2%. This suggests that there is some precision in the assay 
based on the relatively low percentages, and it is reproducible with good success. The coefficient 
of variation for H3k9Ac suggests that there is less precision, with values in the 30s, but the assay 
is highly reproducible given that the range in numbers is relatively tight. 
Table 3. Statistical Analysis of THP-1 Cells at Each Promoter and Histone Modification. 
H3k4me3 TNFalpha IL10-233 IL10-531 IL12-p35 IL12-p40 
Mean 21.88 16.13 14.34 26.73 9.084 
Standard Deviation 3.533 2.306 1.346 6.201 1.227 
Coeff. Of Variation 16.15% 14.30% 9.38% 23.20% 13.50% 
 
H3k9Ac TNFalpha IL10-233 IL10-531 IL12-p35 IL12-p40 
Mean 16.32 3.25 3.768 8.161 3.213 
Standard Deviation 5.334 1.071 1.278 2.669 1.024 
Coeff. Of Variation 32.68% 32.97% 33.91% 32.70% 31.88% 
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Figure 6. Mean with standard deviation of all ChIP assays on Jurkat cells. 
 Analysis of the Jurkat cells, in Figure 6 above, again shows minimal gene activity.  
However, there is a wider spread between the values suggesting less success in repeating the 
assay than in THP-1 cells. The numerical data, in Table 4, supports this belief. The wide ranges 
in the coefficient of variation for both H3k4me3 and H3k9Ac demonstrate a lack of precision 
and reproducibility in this cell line. Because of the many variables inherent in the ChIP assay, 
it’s difficult to pinpoint a reason as to the high variation in some gene targets and not others. 
Table 4. Statistical Analysis of Jurkat Cells at Each Promoter and Histone Modification. 
H3k4me3 TNFalpha IL10-233 IL10-531 IL12-p35 IL12-p40 
Mean 5.764 5.9 6.944 9.491 5.633 
Standard Deviation 1.267 0.4964 1.287 4.046 1.823 
Coeff. Of Variation 21.98% 8.41% 18.54% 42.64% 32.35% 
 
H3k9Ac TNFalpha IL10-233 IL10-531 IL12-p35 IL12-p40 
Mean 8.117 7.249 8.438 8.098 4.803 
Standard Deviation 2.222 3.972 3.391 4.125 0.7613 
Coeff. Of Variation 27.38% 54.78% 40.19% 50.94% 15.85% 
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 In looking at the TF-1a ChIP assays, there is still minimal gene activity, as shown by the 
percent input in Figure 7. There is less variability at each gene than in Jurkat cells, but more than 
in THP-1 cells. While the values in Table 5 are not tight for all genes at H3k4me3, there is good 
reproducibility and there is good precision at both promoter regions of IL10 and at promoter of 
IL12-p35. At H3k9Ac, the numbers suggest reproducibility and precision of the assays is not 
very good, especially at both IL12 promoters. 
 
 
Figure 7. Mean with standard deviation of all ChIP assays on TF-1a cells. 
Table 5. Statistical Analysis of TF-1a Cells at Each Promoter and Histone Modification. 
H3k4me3 TNFalpha IL10-233 IL10-531 IL12-p35 IL12-p40 
Mean 4.722 6.689 6.224 19.86 8.741 
Standard Deviation 1.654 1.441 1.109 2.492 2.891 
Coeff. Of Variation 35.03% 21.54% 17.83% 12.55% 33.07% 
 
H3k9Ac TNFalpha IL10-233 IL10-531 IL12-p35 IL12-p40 
Mean 7.294 7.057 6.37 6.408 4.481 
Standard Deviation 2.381 1.921 1.893 2.747 1.83 
Coeff. Of Variation 32.64% 27.23% 29.72% 42.87% 40.85% 
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Another means of looking at the reproducibility of the ChIP assay was to perform assays 
on the same cell isolations at two different times. Analyzing that data using paired t-tests shows 
that the assay is, with a few exceptions, highly reproducible. A correlation coefficient was also 
calculated to determine how effective the pairing was between the two aliquots. None of the t-
tests suggested any significant differences between the paired samples. Several correlation 
coefficients were significant at p = 0.05, as indicated by an *, and p = 0.01, indicated by **, in 
Figures 8, 9, and 10. In the THP-1 cells, it is interesting to note that none of the r values went 
below 0.9. This observation, paired with the values discussed above in Table 3, suggests that in 
THP-1 cells the ChIP assay is highly reproducible if not necessarily highly precise. One could 
argue that the differences between cell isolation days are the product of biology rather than 
technique. However, there is no pattern of increased or decreased percent input values based on 
the day of cell isolation. In the THP-1 cells in Figure 8, half of the graphs show an increase in 
percent input in Day 2 of cell isolation and then a decrease in Day 3. If the differences between 
days were to be attributable to biology, one would expect a stronger, more consistent pattern.  
Similarly in Jurkat cells, the variability seen in the above data is mirrored in Figure 9. 
There is more variability in the r values, with ranges from 0.7460 to 1.000. Only half of the 
graphs show consistency in the change in percent input between cell isolation days as in THP-1 
cells. This pattern is again repeated in TF-1a cells, as shown in Figure 10. In these two cell lines, 
the little consistency there is shows a decrease in percent input from Day 1 to Day 2, followed by 
an increase from Day 2 to Day 3, with the percent input on Day 3 being larger than Day 1. This 
all suggests that the ChIP assay is highly reproducible and there is the possibility that the 
changes seen in percent input may be due to biology, specifically the potentially altered 
epigenetic machinery in immortalized cell lines. 
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Figure 8. Comparison between aliquots of same THP-1 cells assayed on different days. The lines 
represent the three different days the cells were isolated and crosslinked. 
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Figure 9. Comparison between aliquots of same Jurkat cells assayed on different days. The lines 
represent the three different days the cells were isolated and crosslinked. 
 
0
2
4
6
8
%
 In
p
u
t 
- 
T
N
F
a
lp
h
a
r = 0.9999 **
1
2
3
0
5
10
15
%
 I
n
p
u
t 
- 
T
N
F
a
lp
h
a
r = 0.9458
1
2
3
0
2
4
6
8
%
 In
p
u
t 
- 
IL
1
0
-2
3
3
r = 0.7460
1
2
3
0
5
10
15
%
 In
p
u
t 
- 
IL
1
0
-2
3
3
r = 0.9816
1
2
3
0
2
4
6
8
10
%
 In
p
u
t 
- 
IL
1
0
-5
3
1
r = 08211
1
2
3
0
5
10
15
%
 In
p
u
t 
- 
IL
1
0
-5
3
1
r = 0.9962 *
1
2
3
0
5
10
15
20
%
 In
p
u
t 
- 
IL
1
2
-p
3
5
r = 1.000 **
1
2
3
0
5
10
15
%
 In
p
u
t 
- 
IL
1
2
-p
3
5
r = 0.9997 **
1
2
3
C
hI
P
 1
C
hI
P
 2
0
2
4
6
8
10
ChIP Day H3k4me3
%
 In
p
u
t 
- 
IL
1
2
-p
4
0
r = 0.9581
1
2
3
C
hI
P
 1
C
hI
P
 2
0
2
4
6
8
ChIP Day H3k9Ac
%
 I
n
p
u
t 
- 
IL
1
2
-p
4
0
r = 0.9933 *
1
3
2
CHROMATIN IMMUNOPRECIPITATON 
 30 
  
  
  
 
 
Figure 10. Comparison between aliquots of same TF-1a cells assayed on different days. The 
lines represent the three different days the cells were isolated and crosslinked. 
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 Initial analysis of histone modification in normal individuals involves establishing 
whether the data fulfills the requirements for normal distribution. Normal distribution is 
important, statistically, because most biological variables have a normal distribution. In addition, 
many statistical methods assume sample distribution is normal. Figure 11 illustrates the variation 
in all samples collected for each histone modification at each gene promoter site. Table 6 shows 
that variability ranges from a tight 13.90% to a wider 37.87%. Using the D’Agastino & Pearson 
omnibus normality test indicates that the data are normally distributed.  
 
 
Figure 11. Mean with standard deviation of all ChIP assays on healthy individuals. 
Table 6. Statistical Analysis of PBMCs at Each Promoter and Histone Modification. 
H3k4me3 TNFalpha IL10-233 IL10-531 IL12-p35 IL12-p40 
Mean 25.18 20.09 15.47 28.64 19.52 
Standard Deviation 4.902 6.686 6.099 3.981 6.884 
Coeff. Of Variation 19.47% 33.27% 34.37% 13.90% 35.26% 
Normality Yes Yes Yes Yes Yes 
      H3k9Ac TNFalpha IL10-233 IL10-531 IL12-p35 IL12-p40 
Mean 20.47 19.86 18.61 18.41 18.37 
Standard Deviation 5.454 5.791 5.695 3.741 6.957 
Coeff. Of Variation 24.23% 29.15% 30.61% 20.32% 37.87% 
Normality Yes Yes Yes Yes Yes 
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Two-way analysis of variance (ANOVA) was performed on the data in Figure 12 to 
examine the influence of individuals and time on epigenetic changes for each histone and gene 
loci. While there is no statistical significance of time on the percent input calculated for each 
individual, there is statistical significance regarding the differences between individuals at all 
promoter regions except at H3k4me3 at the TNF promoter. This demonstrates the inherent 
biological variability present in ChIP analysis. Regarding technical variability, it is important to 
investigate epigenetic changes within each individual.  
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g. h. 
i. j. 
Figure 12. Histone modification at gene loci over time between participants. 
Overall, the amount of variability is relatively low for each individual, under 30%, shown 
in Table 7. There are a few exceptions, particularly Subject 4 at IL10-233 and IL12-p40, both at 
H3k4me3. It is difficult to determine if the high variability at these two locations for this one 
individual is attributable to biological changes or technical problems; a problem inherent in using 
ChIP. In looking across values for each histone modification and promoter combination, it is 
interesting to note that there is minimal variation at H3k4me3 at the IL12-p35 promoter site. 
However, in general, there is slightly more variability associated with the modification of H3k4 
than there is at H3k9 across all five patients.  
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Table 7. Statistical Analysis of Human Participants at Each Promoter. 
TNFalpha 
     H3k4me3 Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 
Mean 23.34 23.04 22.58 29.35 27.61 
Standard Deviation 4.515 6.372 4.737 2.281 2.283 
Coeff. Of Variation 19.35% 27.66% 20.98% 7.77% 8.27% 
H3k9Ac Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 
Mean 19.34 17.31 18.09 24.41 25.11 
Standard Deviation 5.173 6.556 3.467 2.687 2.357 
Coeff. Of Variation 26.74% 37.88% 19.16% 11.00% 9.39% 
IL10-233 
     H3k4me3 Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 
Mean 17.61 27.88 18.99 12.98 23.02 
Standard Deviation 3.96 4.806 4.155 6.096 3.677 
Coeff. Of Variation 22.48% 17.24% 21.89% 46.97% 15.97% 
H3k9Ac Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 
Mean 24.4 21.63 17.63 11.19 24.46 
Standard Deviation 3.305 2.822 2.405 2.636 3.568 
Coeff. Of Variation 13.54% 13.05% 13.64% 23.56% 14.58% 
IL10-531 
     H3k4me3 Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 
Mean 20.86 18.32 20.66 10.12 18.79 
Standard Deviation 4.699 4.993 6.072 5.007 3.676 
Coeff. Of Variation 22.53% 27.26% 29.40% 49.49% 19.57% 
H3k9Ac Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 
Mean 18.8 23.53 19.7 9.73 21.27 
Standard Deviation 1.65 4.113 3.902 2.677 3.526 
Coeff. Of Variation 8.77% 17.48% 19.81% 27.51% 16.58% 
IL12-p35 
     H3k4me3 Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 
Mean 31.47 31.07 23.29 28.38 29 
Standard Deviation 3.172 2.414 3.851 2.359 2.065 
Coeff. Of Variation 10.08% 7.77% 16.54% 8.31% 7.12% 
H3k9Ac Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 
Mean 19.03 18.69 16.64 15.66 22.05 
Standard Deviation 3.491 3.062 3.524 2.919 3.071 
Coeff. Of Variation 18.35% 16.39% 21.17% 18.64% 13.93% 
IL12-p40 
     H3k4me3 Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 
Mean 24.43 21.89 23.55 9.452 18.3 
Standard Deviation 3.672 4.133 5.605 4.417 3.858 
Coeff. Of Variation 15.03% 18.88% 23.80% 46.72% 21.08% 
H3k9Ac Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 
Mean 22.85 20.69 21.39 7.298 19.62 
Standard Deviation 4.292 4.883 5.584 2.01 3.57 
Coeff. Of Variation 18.78% 23.60% 26.10% 27.55% 18.19% 
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Chapter 5: Summary, Conclusions, and Recommendations for Further Research 
The human genome contains 23,000 genes that must be expressed in specific cells at 
precise times.  Cells manage gene expression by wrapping DNA around clusters of globular 
histone proteins to form nucleosomes (Rodenhiser, 2006). In general, DNA is wrapped around 
nucleosomes, which are arranged as regularly spaced beads (146 bp DNA/nucleosome) along the 
DNA. Typically, nucleosomes consist of a histone octamer that includes histones H2A/B, H3, 
and H4, with N-terminal histone tails protruding from the nucleosomes (Rodenhiser, 2006). 
There is a large body of evidence showing that modifications of the histone tails provide signals 
that are recognized by specific binding proteins that in turn influence gene expression and other 
chromatin functions. Specific sets of histone modifications and/or variants are associated with 
genes that are actively transcribed or are repressed, a phenomenon defined as the “histone code” 
(Vanden Berghe, 2006). This histone code results in a conformation change in the chromatin: 
genes are inactivated (switched off) when the chromatin is condensed (silent), and they are 
expressed (switched on) when chromatin is open (active); (Roundtree, 2001). 
 Histone-modifying enzymes are recruited to ensure that a receptive DNA region is either 
accessible for transcription or that DNA is targeted for silencing. Lysine methylation displays the 
highest degree of complexity among known covalent modifications, and each site of methylation 
can influence gene activity independently (Hirst & Marra, 2009). Thus, an epigenetic “tag” is 
placed on targeted DNA, marking it with a special status that specifically activates or silences 
genes. These reversible modifications ensure that specific genes can be expressed or silenced 
depending on specific developmental or biochemical cues, such as changes in hormone levels, 
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inflammation, dietary components, or drug exposures (Rodenhiser, 2006). Epigenetic 
mechanisms regulate DNA accessibility throughout a person’s lifetime. 
Research has shown that epigenetic mechanisms provide an "extra" layer of 
transcriptional control that regulates how genes are expressed. Many of these transcriptional 
changes occur during development and are subsequently retained through cell proliferation.  
Epigenetic changes can also arise in adults either by random change or under the effects of the 
environment, aging, chronic inflammation, stress, viral/bacterial infections, diet, hormones, and 
toxins (Vande Berghe, 2006).  Epigenetic abnormalities have been found to be causative factors 
in cancer, genetic disorders, and pediatric syndromes as well as contributing factors in 
autoimmune diseases and aging (Egger et al, 2004). The activation of the immune response 
involves stepwise epigenetic changes, which allow individual cells to mount a specific immune 
response that can be maintained over multiple cell generations. For example, shifts in both 
acetylation and methylation of lysines are required to coordinate DNA accessibility and permit 
recombination, thereby allowing cells to mount an immune response against a specific antigen 
(Rodenhiser, 2006).  
One of the most intensely studied lysine modifications is histone H3 lysine 4 
trimethylation (H3K4me3). H3K4me3 has been shown to recruit downstream effectors, rather 
than directly affect transcription (Hirst and Marra, 2009). Downstream areas of interest in the 
study of inflammation are the promoter sites for TNF, IL-10, IL-12. Sullivan (2007) was able 
to demonstrate that TNF expression increased when Histone 3 was acetylated and that 
inhibition of histone methylation reduced TNF expression in cells capable of producing TNF. 
Larrson’s study (2012) showed increased IL10 expression when Histone 3 was acetylated and 
also when Histone 3 lysine 4 was trimethlyated. Jin (2016) recently demonstrated that IL12 
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expression increased with trimethylation of H3k4, and Lu et al. (2005) showed that Histone 3 
acetylation stimulated expression of the IL12 p40 promoter.  
Chromatin Immunoprecipitation (ChIP) is a type of immunoprecipitation experimental 
technique used to investigate the interaction between proteins and DNA in the cell. Association 
between proteins and DNA is crucial for many vital cellular functions such as gene transcription, 
DNA replication and recombination, repair, segregation, chromosomal stability, cell cycle 
progression, and epigenetic silencing. It is important to know the genomic targets of DNA-
binding proteins and the mechanisms by which they control and guide gene regulation pathways 
and cellular proliferation (Das et al., 2004). ChIP aims to determine the specific location in the 
genome that various histone modifications are associated with, indicating the target of the 
histone modifiers. Because of the sensitive nature of the technique, it is difficult to adapt to a 
clinical setting or for high-throughput screening. This is especially difficult in the pediatric 
population due to limitations in tissue sample sizes. The goal of this study was to demonstrate 
reproducibility with small cell volumes (~1 million cells) and reliability in small cell numbers 
isolated whole blood drawn from healthy adult volunteers.  
This study presents data that establishes, for the first time, the normal variability of ChIP 
results in THP-1 cells, Jurkat cells, TF-1a cells, and human male circulating leukocytes over time 
for H3k4me3 and H3k9Ac. The results from this study allow us to begin establishing a normal 
range for ChIP assays, which is important in interpreting future ChIP results from patient 
samples. Several therapeutics involve disruption histone modifications, so an understanding of 
what occurs in a healthy individual becomes important in determining the safety and efficacy of 
clinical intervention using these therapeutics. This study provides a baseline for understanding 
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the role of histone modification and gene expression. The study needs to be expanded beyond 
more than five male individuals to include healthy females, the elderly, and children. 
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occur, you must notify the IRB Office as soon as possible. 
AEs/ORIOs: 
You must continue to inform the IRB of all unanticipated events, adverse events (AEs), and 
other reportable information and occurrences (ORIOs). These include but are not limited 
to events and/or information that may have physical, psychological, social, legal, or 
economic impact on the research subjects or others. 
Investigators and research staff are responsible for reporting information concerning the 
approved research to the IRB in a timely fashion, understanding and adhering to the 
reporting guidance (http://medicine.umich.edu/medschool/research/office-
research/institutional-review-boards/guidance/adverse-events-aes-other-reportable-
information-and-occurrences-orios-and-other-required-reporting), and not implementing 
any changes to the research without IRB approval of the change via an amendment 
submission. When changes are necessary to eliminate apparent immediate hazards to the 
subject, implement the change and report via an ORIO and/or amendment submission 
within 7 days after the action is taken. This includes all information with the potential to 
impact the risk or benefit assessments of the research. 
 
 
SUBMITTING VIA eRESEARCH: 
You can access the online forms for continuing review, amendments, and AE/ORIO 
reporting in the eResearch workspace for this approved study, referenced above. 
MORE INFORMATION: 
You can find additional information about UM’s Human Research Protection Program 
(HRPP) in the Operations Manual and other documents available 
at: http://hrpp.umich.edu. 
 
 
Michael Geisser 
Co-chair, IRBMED 
Alan Sugar 
Co-chair, IRBMED 
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Appendix B: Eastern Michigan University IRB Not Research Letter 
 
RESEARCH @ EMU  
UHSRC Determination: NO REVIEW REQUIRED  
DATE: June 29, 2016  
TO: Kelli McDonough, Eastern Michigan university  
Re: UHSRC: # 904014-1   
Category: Not Human Subject Research  
Title: Reproducibility and reliability of chromatin immunoprecipitation in clinical research  
Your project, entitled Reproducibility and reliability of chromatin immunoprecipitation in 
clinical research, does not require UHSRC review in accordance with federal regulation 45 
CFR 46.102 because you are using already-obtained blood samples. UHSRC policy states that 
you, as the Principal Investigator, are responsible for protecting the rights and welfare of your 
research subjects and conducting your study as described in your protocol.  
Modifications: You may make changes to your study without submitting for review. However, if 
you plan to publish your data or collect human subject data that are generalizable, you must 
submit a Human Subjects Approval Request Form and obtain approval prior to 
implementation. The form is available through IRBNet on the UHSRC website.  
Good luck in your research. If we can be of further assistance, please contact us at 734-487-
3090 or via e-mail at human.subjects@emich.edu. Thank you for your cooperation.  
Sincerely,  
Sonia Chawla, PhD  
Reaserch Compliance Officer  
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